DGAP-News: Biotest AG: Biotest AG's Supervisory Board extends the term of CEO Prof. Schulz and appoints Dr. Floßto the Board of Management
(firmenpresse) - DGAP-News: Biotest AG / Key word(s): Change of Personnel
Biotest AG: Biotest AG's Supervisory Board extends the term of CEO
Prof. Schulz and appoints Dr. Floßto the Board of Management
09.01.2013 / 14:00
---------------------------------------------------------------------
/
PRESS RELEASE
Biotest AG's Supervisory Board extends the term of CEO Prof. Schulz and
appoints Dr. Floßto the Board of Management
Dreieich, January 9, 2013: Today the Supervisory Board of Biotest AG
extended the term of CEO Prof. Dr. Gregor Schulz till December 31, 2014.
Prof. Schulz manages the Biotest Group as Chairman of the Board of
Management since ten years. In this period revenues have been doubled and
the operating loss of EUR -1.7 m has been turned in positive earnings
(EBIT) of more than EUR 42 m.
Since in the meantime Biotest Group is producing its pharmaceutical
products in Dreieich in Germany as well as in Boca Raton, USA, and wants to
continue growing,the Supervisory Board has appointed Dr. Georg Floßto the
Board of Management effective January 9, 2013. As 'Chief Operating Officer'
he will be responsible for production and operations. Dr. Floßjoined
Biotest in February 2008 as head of production in Dreieich. In 2010/11 he
was also responsible for the extension and expansion of Biotest's
activities in Boca Raton, Florida, USA.
Besides Prof. Schulz and Dr. Floß, Dr. Michael Ramroth continues to be a
member of the Board of Management responsible for finance and central
services.
The Chairman of the Supervisory Board, Dr. Alessandro Banchi, thanked Prof.
Schulz explicitly for his very successful ten year term of service as CEO
and his willingness to continue as CEO till end of 2014 beyond the
originally agreed term. 'With the appointment of Dr. Floßto the Board of
Management we wanted to strengthen also the human management resources for
continued growth of the group', emphasized Dr. Banchi.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
application of clinical immunology, haematology and intensive medicine. In
its Plasma Protein portfolio Biotest develops and markets immunoglobulins,
coagulation factors and albumins based on human blood plasma. These are
used for diseases of the immune and haematopoietic systems. Biotest also
researches into the development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and cancer of plasma cells. Biotest has
more than 1.600 employees worldwide. The preference shares of Biotest AG
are listed in the SDAX on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations(at)biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
End of Corporate News
---------------------------------------------------------------------
09.01.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations(at)biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
198666 09.01.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="EXETER BEGINS WATER EXPLORATION DRILLING FOR ITS CASPICHE GOLD-COPPER PROJECT, CHILE
Datum: 09.01.2013 - 14:00 Uhr
Sprache: Deutsch
News-ID 217973
Anzahl Zeichen: 5353
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 285 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Biotest AG: Biotest AG's Supervisory Board extends the term of CEO Prof. Schulz and appoints Dr. Floßto the Board of Management"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotest AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
